Clinical Trials Logo

Polycystic Liver Disease clinical trials

View clinical trials related to Polycystic Liver Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05281328 Active, not recruiting - Clinical trials for Polycystic Liver Disease

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

POSITANO
Start date: June 28, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of CAM2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic PLD, either isolated as in autosomal dominant PLD (ADPLD) or associated with autosomal dominant polycystic kidney disease (ADPKD). In the Treatment Period of the trial, participants will be allocated at random to 1 of the 3 treatment arms in a 1:1:1 ratio. After completing the Treatment Period (53 weeks) participants may proceed to a 24-week open-label extension part of the trial and then only receive the same CAM2029 treatment. The active ingredient in CAM2029, octreotide, is administered as a subcutaneous depot using Camurus' FluidCrystal® technology.

NCT ID: NCT00771888 Active, not recruiting - Liver Diseases Clinical Trials

Open-Label Extension of LOCKCYST Trial

LOCKCYST-ext
Start date: April 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available. Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.